Meet the team

Helio has served in corporate development capacities for a number of companies and has a strong aptitude for operations. He offers a scientific business development strategy, including therapeutic portfolio development, innovative products, licensing opportunities, regulatory feasibility, marketing, and access analysis. MBA in Health Economics and Health Systems. Previously, he served as President of the SBMF (Brazilian Association of Pharmaceutical Medicine), a medical society that congregates health professionals working in the pharmaceutical industry.

With two decades in the health industry, Henrique has forged significant pharmaceutical partnerships and spearheaded international business development initiatives, positioning him as force in bringing Network Immunology’s technologies to the global market.

Hadley is a seasoned science communicator with a background academic research. Passionate about bridging the gap between science and the public, Hadley seeks to integrate science communication into Network Immunology’s initiatives, fostering meaningful connections and promoting awareness of our innovative immunotherapeutic solutions for inflammatory diseases.

Douglas has a proven track record of driving brand and product success across various industries, including stem cell medicine, hydrogen energy, 3D Printing, and So Good/So Nice Soy beverage in North America. His expertise in corporate development, investor relations, and appropriate capital infusion has been pivotal in elevating Network Immunology’s position in the biotech market.

George has led Network Immunology since the advent of the Company’s AbstimX™ platform technology and therapy, taking it from the concept stage to the veterinary clinical stage and to the verge of licensing and commercialization. He has led the raise of approximately CAD $2M and built an outstanding Executive Team to commercialize NI’s world-changing AbstimX™ technology. George has 15 years of full-time experience in biotech business administration, capital raising, strategic corporate development, and building executive and scientific teams.

John’s extensive leadership experience is characterized by a commitment to operational excellence and strategic growth. With a passion for innovation and a globetrotting spirit, he ensures that Network Immunology remains at the forefront of the biotech industry.

Aaron brings over 15 years of experience in health and management consulting, blending operational excellence with mission-driven innovation. As head of operations, he builds resilient systems that drive impact, streamline execution, and advance Network Immunology’s mission to strengthen immune systems worldwide.

Natalia Meissner is a Switzerland-based CFO with 25+ years of experience in high-growth, tech-driven industries. She brings deep expertise in M&A integration, financial performance, and operational optimization, backed by an MBA, CPA, and PMI certifications. Known for driving value through strategic planning and sustainability-focused initiatives.

Randy brings over 20 years of leadership experience in business development, sales, and marketing within the veterinary and biotech industries. His expertise in optimizing commercial operations positions the company for strong global growth.

Anthony holds over two decades of business, operations, product development, and scientific experience with a sound clinical understanding in personalised Medicine, Drug and Biomarker Development, Health and Wellness (Food), Autoimmunity, Gastroenterology, Pathology, and Oncology.
He has served in corporate development capacities for a number of companies, and has a strong aptitude for operations.

Alexis specializes in the development and commercialization of animal health therapies. As veterinary doctor with 26 years of experience in animal therapeutic development and an additional 9 in human therapeutic development, he leads Network Immunology's advancement of immuno-therapeutics for inflammatory diseases in animals while furthering the vision and plan of applying NI's technology to human clinical applications. His strategic, collaborative approach enhances our innovation, steering Network Immunology towards significant global impact with both veterinary and human medicine.